350 Participants Needed

Education and Screening for Hepatitis C and Colorectal Cancer

(MATCHES Trial)

CB
SC
Overseen ByShannon Christy, PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to promote screening for colorectal cancer and hepatitis C among patients at certain health clinics. Participants will receive educational materials, free stool-based tests for colorectal cancer, and free hepatitis C antibody testing. The trial targets individuals aged 45-75 who have not recently undergone a colonoscopy or hepatitis C screening and have no history of colorectal cancer or current symptoms. Participants should be able to read and understand English or Spanish and be willing to complete surveys or interviews. As an unphased trial, this study offers a unique opportunity to contribute to important public health research and potentially improve screening practices.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What prior data suggests that the MATCHES intervention is safe for patients?

Research has shown that the MATCHES program focuses on educating people and screening for hepatitis C (HCV) and colorectal cancer (CRC). It provides information and tests, which are generally safe.

No reports of negative effects have emerged from the educational materials or screening tests used in the MATCHES program. The tests include a stool test for CRC and a blood test for HCV, both easy to perform and generally comfortable for patients.

Studies on HCV have found that patients who received treatment for their infection had a lower risk of developing colon cancer compared to those who did not receive treatment. This suggests the program could be beneficial. The safety of these tests and educational materials is well-established, with no significant risks reported.12345

Why are researchers excited about this trial?

Researchers are excited about the MATCHES intervention because it combines education with proactive screening for both colorectal cancer (CRC) and hepatitis C (HCV), targeting these issues simultaneously. Unlike standard treatments that focus on one condition at a time, MATCHES offers a comprehensive approach by providing patients with educational booklets in English or Spanish, free stool-based CRC screening, and free HCV antibody testing. This multi-pronged strategy not only raises awareness but also improves access to preventative care, potentially increasing early detection rates and improving overall health outcomes.

What evidence suggests that the MATCHES intervention is effective for promoting HCV and CRC screening?

Research has shown that education and free screening significantly increase the number of people getting checked for colorectal cancer (CRC) and Hepatitis C Virus (HCV). In this trial, participants will receive the MATCHES intervention, which includes education and free screening. One study found that stool tests reduced new CRC cases by 25%, indicating that testing stool samples can help find cancer early. For HCV, combining education with free testing raises awareness and encourages testing. Both approaches aim to detect diseases early, which is crucial for effective treatment and better health outcomes.678910

Who Is on the Research Team?

SC

Shannon Christy, PhD

Principal Investigator

Moffitt Cancer Center

CK

Clement K Gwede, PhD, MPH, RN, FAAN

Principal Investigator

Moffitt Cancer Center

Are You a Good Fit for This Trial?

The MATCHES trial is for English or Spanish-speaking individuals aged 45-75 who have never been screened for Hepatitis C Virus (HCV), are at average risk for colorectal cancer (CRC), and aren't up to date with CRC screening. They must be willing to complete surveys, interviews via phone or video call, and provide informed consent. Those with a personal history of CRC, current symptoms, or not receiving care at participating clinics are excluded.

Inclusion Criteria

I am willing to do an interview over the phone or on a video call.
I can read, write, and understand English or Spanish.
I am willing and able to complete surveys and receive the intervention.
See 10 more

Exclusion Criteria

Participants that do not meet all Inclusion Eligibility requirements will be excluded

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Education and Initial Screening

Participants receive education about CRC and HCV and access to free stool-based CRC screening and HCV antibody testing

12 months
Multiple visits as needed for education and screening

Follow-up

Participants are monitored for screening uptake and completion of CRC and HCV screenings

Up to 41 months

What Are the Treatments Tested in This Trial?

Interventions

  • MATCHES
Trial Overview MATCHES is testing an educational intervention designed to encourage simultaneous screening for HCV and CRC in patients attending Federally Qualified Health Centers (FQHCs). The study involves providing materials, completing surveys, and possibly participating in remote interviews.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening (MATCHES)Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

H. Lee Moffitt Cancer Center and Research Institute

Lead Sponsor

Trials
576
Recruited
145,000+

Florida Biomedical Research Program - Bankhead Coley

Collaborator

Trials
1
Recruited
350+

Published Research Related to This Trial

A study analyzing data from 6890 colorectal cancer patients in New South Wales found significant variations in care processes across 105 hospitals, particularly affecting older adults who were less likely to receive timely treatment and multidisciplinary discussions.
Patient characteristics, such as age, disease extent, and comorbidity scores, were strongly linked to poorer outcomes, suggesting that these factors should be considered when comparing hospital performance and outcomes.
Predictors of variation in colorectal cancer care and outcomes in New South Wales: a population-based health data linkage study.Jorgensen, ML., Young, JM., Dobbins, TA., et al.[2019]
An electronic primer message sent through a patient portal significantly increased colorectal cancer (CRC) screening completion rates from 32.1% to 37.6% in a study of 2339 average-risk patients aged 50 to 75 years.
Patients who opened the electronic primer message had a 7.3% higher screening completion rate, and the time to complete screening was also shorter in the intervention group, indicating that digital reminders can effectively enhance participation in CRC screening programs.
Effect of Patient Portal Messaging Before Mailing Fecal Immunochemical Test Kit on Colorectal Cancer Screening Rates: A Randomized Clinical Trial.Goshgarian, G., Sorourdi, C., May, FP., et al.[2022]
In a 3-year study involving 33,606 patients at a Central Texas Federally Qualified Health Center, 19.9% completed a mailed stool test for colorectal cancer screening, demonstrating the effectiveness of this outreach method.
The program showed significant equity in screening uptake, with Hispanic/Latinx and Spanish-speaking patients participating more than their white and English-speaking counterparts, and Spanish speakers also had higher rates of completing follow-up colonoscopies after positive test results.
Equitable Implementation of Mailed Stool Test-Based Colorectal Cancer Screening and Patient Navigation in a Safety Net Health System.Scott, RE., Chang, P., Kluz, N., et al.[2023]

Citations

protocol for a large cluster-randomized implementation studyComparative effectiveness of two interventions to increase colorectal cancer screening for those at increased risk based on family history ...
Long-Term Effectiveness Associated With Fecal ...The results showed a statistically significant 25% reduction in CRC incidence (aRR, 0.75; 95% CI, 0.72-0.77) and a 34% reduction in CRC ...
Factors associated with prior completion of colorectal cancer ...To examine psychosocial factors associated with completion of CRC and HCV screenings in order to inform a multi-behavioral educational intervention.
Protocol for a Multilevel Intervention to Improve Screening ...The primary outcome is the completion rate of CRC screening at 90 days. Secondary outcomes include the screening completion rate at 180 days and the rate of ...
Digital health interventions for colorectal cancer screening ...This scoping review examines how individual, contextual, technological, and timing-related factors shape CRC screening outcomes in DHI-based trials. Following ...
Patients With Chronic Hepatitis C Virus Infection Are at an ...Our findings suggested that patients with chronic HCV infection are at an elevated risk of developing CRC.
Different Metabolic Associations of Hepatitis C With Colon ...The HCV-untreated cohort had the highest cumulative incidence of CC (0.883%; 0.371-1.839%), while HCV-treated (0.478%; 0.110-1.518%) and HCV-uninfected cohorts ...
Multilevel Action Toward Colorectal Cancer and Hepatitis C ...The MATCHES intervention includes three patient-level intervention strategies that will be rolled out in two waves. Patient-level strategies are: 1) a combined ...
Hepatitis C Infection May Increase Colon Cancer Risk, But ...Hepatitis C infection and age 49 years and older is linked to a higher risk of developing colorectal cancer.
Strategies to Promote Colorectal Cancer and Hepatitis C ...MATCHES may increase CRC and HCV screening and reduce CRC and liver cancer mortality among patients aged 45-75. Eligibility Criteria ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security